Home>>Peptides>>Motilin, canine (Motilin (canine))

Motilin, canine (Motilin (canine)) (Synonyms: Motilin (canine))

Catalog No.GC31500

Motilin, canine (Motilin (canine)) is a 22-amino acid peptide.

Products are for research use only. Not for human use. We do not sell to patients.

Motilin, canine (Motilin (canine)) Chemical Structure

Cas No.: 85490-53-5

Size Price Stock Qty
1mg
$175.00
In stock
5mg
$450.00
In stock
10mg
$726.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Motilin, canine is a 22-amino acid peptide. Motilin is a potent agonist for gastrointestinal smooth muscle contraction.

Motilin is a potent agonist for gastrointestinal smooth muscle contraction and has been proposed to regulate the onset of phase III of the migrating motor complex (MMC) in dogs and humans. In the dog, but not in the human, Motilin also contracts the gallbladder and sphincter of Oddi and induces pancreatic secretion. Motilin activates L-type Ca2+ channel (IcaL) in canine jejunal circular smooth muscle cells through a G protein-coupled mechanism. At 1 μM, Motilin increases IcaL in canine jejunal circular smooth muscle cells by 43±20[1].

[1]. Farrugia G, et al. Motilin and OHM-11526 activate a calcium current in human and canine jejunal circular smooth muscle. Am J Physiol. 1997 Aug;273(2 Pt 1):G404-12.

Reviews

Review for Motilin, canine (Motilin (canine))

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Motilin, canine (Motilin (canine))

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.